stockrowLigand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.
- Revenue
- −31.8%
- EPS
- −123.9%
- Free cash flow
- −268.5%
- Total debt
- +52.6%
Quarter to September 2026, against a year earlier
Follow LGND
Alert me
Ligand Pharmaceuticals Incorporated (LGND) Shares outstanding
Ligand Pharmaceuticals Incorporated's shares outstanding at the end of fiscal 2025 was $20.3M, up 11.0% from $18.3M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $20.0M. Over the past ten years it has ranged from $16.8M (fiscal 2020) to $24.1M (fiscal 2018); the current reading is higher than 64% of that period. Ligand Pharmaceuticals Incorporated ranks 402nd of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $20.3M | 10.96% |
| FY2024 | $18.3M | 3.00% |
| FY2023 | $17.8M | 5.27% |
| FY2022 | $16.9M | (2.19%) |
| FY2021 | $17.2M | 2.50% |
| FY2020 | $16.8M | (14.84%) |
| FY2019 | $19.8M | (17.91%) |
| FY2018 | $24.1M | 2.50% |
| FY2017 | $23.5M | 12.72% |
| FY2016 | $20.8M | (1.87%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $20.0M | (8.59%) |
| Jun 2026 | $21.8M | 9.83% |
| Mar 2026 | $19.9M | (2.03%) |
| Dec 2025 | $20.3M | (1.62%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IMVT Immunovant, Inc. compare | $205.5M |
| IONS Ionis Pharmaceuticals, Inc. compare | $165.4M |
| CGON CG Oncology, Inc. compare | $88.2M |
| PTCT PTC Therapeutics, Inc. compare | $83.5M |
| MIRM Mirum Pharmaceuticals, Inc. compare | $66.1M |
| ORKA Oruka Therapeutics, Inc. compare | $62.9M |
| KOD Kodiak Sciences Inc. compare | $62.6M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | $40.2M |
| LGND Ligand Pharmaceuticals Incorporated | $20.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on LGND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement